Navigation Links
Exelixis Sells 80% Stake in Artemis to Taconic
Date:11/20/2007

uctive relationship in the future."

Under the terms of the agreement, Taconic paid Exelixis approximately $20 million, subject to certain post-closing adjustments, in exchange for an 80.1% ownership position in Artemis. Exelixis has the option to sell its remaining interest to Taconic, and Taconic also has an option to purchase Exelixis' remaining interest during certain times and under certain circumstances through 2015.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

About Artemis

Artemis has developed a versatile technology platform in mouse genetics and functional genomics. The company offers custom made genetically engineered mouse models as in vivo genetic model systems for use at various stages of the drug discovery process or in academic research. Models produced by the ArteMice(TM) platform include knock out and "humanization" platforms and platforms for generating inducible/reversible RNAi knock down models and ASKA models for the inducible and reversible knock down of kinases. These platforms are being continually expanded, most recently with the addition of mouse models humanized for key drug metabolism enzyme
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... July 27, 2015 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: ... and commercializing products for the treatment of cancer, today ... that it has closed a $1,000,000 unit offering private ... 16,666,667 units of the Company at a price of ... common share and one common share purchase warrant.  Each ...
(Date:7/27/2015)... , July 27, 2015   Inocucor ... produces sustainable biological accelerators for farmers, has received ... and Trademark Office for its patent application to ... accelerate plant growth and enhance yields on farms ... relates to Inocucor,s live IN-M1 microbial consortium and ...
(Date:7/27/2015)... YORK , July 27, 2015 ... today announced the winners of its annual Klerman ... research by scientists who have been supported by ... career scientists to pursue innovative ideas in neurobiological ... "proof" of concept for the early detection, treatment, ...
(Date:7/26/2015)... ... July 26, 2015 , ... ... ANEMIA calibration verification / linearity test kit. The VALIDATE® ANEMIA kit contains Ferritin, ... kit is prepared using the CLSI recommended “equal delta” method for linearity testing ...
Breaking Biology Technology:Quest PharmaTech Closes $1,000,000 Private Placement 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2
... research team at the University of Wisconsin-Madison will ... study the impact of digital media on youth culture, learning, ... support 24 national studies of different aspects of the digital ... MacArthur is actually trying to do, with this grant to ...
... program authorized by the Circuit Court of Wisconsin ... consumers and businesses that acquired Microsoft software ... nearly $224 million back to them as part of ... software giant. , ,The notices are the result of ...
... - For Milwaukee's forthcoming wireless Internet service, everything seems to ... has finalized a contract with Midwest Fiber Networks, LLC ... off the hook because Midwest Fiber will invest the $20 ... begun to install antennas in a demonstration area containing ...
Cached Biology Technology:UW gets $3M to explore educational gaming 2UW gets $3M to explore educational gaming 3Microsoft to distribute $224M as part of settlement 2Will wireless Internet bypass the central city? 2Will wireless Internet bypass the central city? 3Will wireless Internet bypass the central city? 4
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... from livestock waste is possible using a process developed ... invention could help streamline on-farm nitrogen management by allowing ... nitrogen in a liquid product to sell as fertilizer. ... Research Service (ARS) scientists Matias Vanotti and Ariel Szogi ...
... Colo., AMSTERDAM and VIENNA, Nov. 1, 2012 BiOptix today ... the first commercially available SPR instrument to incorporate phase-based common ... in Amsterdam from November 1 - 3 as well ... 6 – 8.  "At the Label Free ...
... team at the National Institute of Standards and Technology ... of how a group of cells will react and ... how quickly. The NIST model, in principle, makes it ... of a population of cells, a critical capability for ...
Cached Biology News:USDA patents method to reduce ammonia emissions 2BiOptix to highlight new 404pi instrument at European symposia 2Cellular landscaping: Predicting how, and how fast, cells will change 2
... Dideoxycytidine is a cytidine analog that has been ... Immunogen: Chemical / Small Molecule ... specificity of the ddC antiserum was determined by ... to moles of ddC analog at the 50% ...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
... a variety of motion options - roller, ... unit. Shake, rock, roll and rotate motions!,, ... hybridization and blotting procedures requiring different settings, ... chamber uses a roller action to operate ...
... the SPD series takes the 'Classic' series ... The SPD121P SpeedVac comes equipped with a ... preventing samples from freezing; and allowing runs ... preset level., Standard features on the SPD121P ...
Biology Products: